Purpose built for personalized precision
Unparalleled sensitivity and specificity for confident MRD detection. Interested in learning more about using Haystack MRD™?
Unparalleled sensitivity
Haystack MRD™
MRD testing demands the most sensitive ctDNA detection. The Haystack MRD test is a tumor-informed ctDNA test that is specifically designed for post-surgical MRD applications.
Residual disease detection
Go beyond standard risk assessment for adjuvant chemotherapy guidance to ensure the right treatment for the right person at the right time.
Treatment response monitoring
Track ctDNA levels during adjuvant chemotherapy or second-line therapy to monitor treatment response and acquired resistance.
Disease recurrence surveillance
Detect molecular recurrence with greater lead time before clinical relapse.
Transformative precision
Dive deeper
Haystack Oncology was founded to dramatically improve patient outcomes by helping doctors optimize treatment strategies using transformative precision oncology. Learn how we support clinicians and biopharma in our mission by providing better MRD testing for better clinical management and therapeutic development.
The difference
What separates us from the rest of the stack?
Analytical superiority
Haystack MRD achieves unmatched sensitivity and specificity for the most effective ctDNA detection.
Transformative technology
Built by giants
Haystack Oncology was founded by pioneers in blood-based diagnostics who were the first to envision a revolution in patient care made possible by groundbreaking molecular methods.
Haystack MRD
In the news
Find out what’s happening at Haystack Oncology and stay up-to-date with industry news.
American Association for Cancer Research 2024
Haystack MRD™ by Quest Diagnostics® will be attending the 2024 American Association for Cancer Research (AACR) annual meeting taking place April 5–10, 2024 in San Diego, CA. The AACR annual meeting stands as the cornerstone of the cancer research community, serving as a gathering point for scientists, clinicians, healthcare practitioners, survivors, patients, and advocates.
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus’ TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.
Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT's interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable stage III non-small cell lung cancer (NSCLC).
